Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Generic Pharmaceuticals Contract Manufacturing Industry Expected To Reach By 2029, Starting From 2025 Levels?
The generic pharmaceuticals contract manufacturing market size has shown robust expansion over recent years. It is anticipated to expand from $62.30 billion in 2024 to $66.82 billion in 2025, recording a compound annual growth rate (CAGR) of 7.3%. This historical growth can be linked to several factors, including an elevated demand for affordable medicines, an increase in healthcare spending across developing nations, the expiry of patents for branded drugs, a rise in outsourcing activities by pharmaceutical companies, and the escalating prevalence of chronic conditions.
The generic pharmaceuticals contract manufacturing market is projected to experience substantial growth over the coming years. This market is set to reach a valuation of $87.59 billion by 2029, expanding at a compound annual growth rate (CAGR) of 7.0%. Factors driving this expansion during the projected period include an increasing emphasis on specialty generics, enhanced government backing for generic medication usage, broader healthcare accessibility in developing economies, escalating investments in contract manufacturing sites, and a rising demand for adaptable and scalable production methods. Key developments anticipated during the forecast timeframe encompass improvements in manufacturing automation, sophisticated quality control techniques, the creation of intricate generic formulations, breakthroughs in drug delivery systems, and progress in continuous manufacturing processes.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
Which Drivers Are Impacting The Generic Pharmaceuticals Contract Manufacturing Market?
The expanding need for biosimilars is projected to fuel the advancement of the generic pharmaceuticals contract manufacturing market. These products are biologic medical treatments closely resembling established reference biologics, possessing no notable clinical variances in terms of safety, purity, or effectiveness. This increasing demand stems largely from their capacity to offer economical substitutes for costly biologic medications, thereby enhancing access to sophisticated treatments for both patients and healthcare providers. Contract manufacturing in generic pharmaceuticals facilitates biosimilar development by offering efficient, high-volume production and essential regulatory knowledge, which helps speed up market introduction and maintain uniform quality. For illustration, in February 2022, Cardinal Health Inc., a healthcare firm based in the US, reported that by January 2022, the US Food and Drug Administration (FDA) had approved 33 biosimilar products, with 21 of these accessible in the market. Moreover, by January 2023, the count of FDA-approved biosimilars climbed to 40, with 25 becoming commercially accessible within 2023. Consequently, the growing need for biosimilars is stimulating the expansion of the generic pharmaceuticals contract manufacturing market.
What Are The Leading Segments Analyzed In The Generic Pharmaceuticals Contract Manufacturing Market?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
Which Competitive Trends Are Defining The Generic Pharmaceuticals Contract Manufacturing Market Structure?
Leading companies in the generic pharmaceutical contract manufacturing market are broadening their service offerings by establishing dedicated subsidiaries, addressing the increasing demand for outsourced development and manufacturing. This deliberate move to create specialized subdivisions enables organizations to streamline the production of active pharmaceutical ingredients (APIs), ensuring compliance, scalability, and operational efficiency across the entire drug development lifecycle. For example, in July 2025, Lupin, an India-based generic pharmaceutical company, unveiled its new subsidiary, Lupin Manufacturing Solutions (LMS), specifically to enter the contract development and manufacturing organization (CDMO) market. This specialized division is focused on supporting the development, manufacturing, and sale of APIs for global pharmaceutical partners. Guided by a leadership team with extensive experience in biotech and pharma, the subsidiary is well-positioned to deliver premium contract services, helping pharmaceutical companies accelerate their time-to-market while upholding regulatory standards and cost-effectiveness.
Which Global Market Leaders Are Shaping The Future Of The Generic Pharmaceuticals Contract Manufacturing Sector?
Major companies operating in the generic pharmaceuticals contract manufacturing market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Fresenius Kabi AG, WuXi AppTec Co. Ltd., Aurobindo Pharma, Cipla Limited, Recipharm AB, Siegfried Holding AG, Curia Global Inc., Torrent Pharmaceuticals Limited., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Pfizer CentreOne, Syngene International Ltd., Wockhardt Ltd., Alcami Corp. Inc, Neuland Laboratories Limited., Panacea Biotec Ltd., Jubilant Generics Ltd.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Generic Pharmaceuticals Contract Manufacturing Industry?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Generic Pharmaceuticals Contract Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25771&type=smp
Browse Through More Reports Similar to the Global Generic Pharmaceuticals Contract Manufacturing Market 2025, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Global Market Report 2025
Biopharmaceuticals Contract Manufacturing Global Market Report 2025
Pharmaceutical Contract Packaging Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model